Boltz, an MIT spinout, closed a 110 million dollar Series A led by Bessemer with Andreessen Horowitz participating. It sells biomolecular foundation models by the token, and paid usage grew roughly 50-fold in four months.
Key facts
- 110 million dollar Series A, after a 28 million dollar seed in January.
- Six of the top 20 drugmakers are paying customers, including Pfizer, GSK, Takeda and Bristol Myers Squibb.
- Open source models have more than 5 million downloads.
- Boltz says a validated hit can cost as little as 10,000 dollars.
Full analysis: https://www.threerouter.com/blog/494
Sources: Endpoints News, Newscast Tech, Off Sand Hill, threerouter

Top comments (0)